FDA Considers Allowing "Broad Disease Information" In DTC Ads
This article was originally published in The Pink Sheet Daily
A planned study will examine the impact of including descriptions of the disease that go beyond a product's labeled claims.
You may also be interested in...
Certain drug classes will be required to submit certain types of ads, according to Tom Abrams, director of CDER’s recently elevated Office of Prescription Drug Promotion, but specifics will await the guidance itself.
The messages conveyed through pharmaceutical direct-to-consumer advertising, and FDA’s role in regulating such promotions, are ripe for re-examination, Commissioner Margaret Hamburg said July 25.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.